- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03009162
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Renal Function
This is a multi-center, open-label, non-randomized, parallel-group, adaptive, single dose study.
This study will enroll up to 32 participants using an adaptive design that can include up to 3 groups of 8 participants with different degree of renal impairment and one group of 8 control participants with normal renal function.
Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered in the study.
First, approximately 16 participants will be enrolled with severe renal impairment and matched participants with normal renal function. There will be 8 participants in each of the following groups based on renal function at screening:
- Group 1: Healthy participants with normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 milliliters per minute per 1.73 meters squared [mL/min/1.73m²])
- Group 2: Severe renal impairment participants (eGFR < 30 mL/min/1.73m²) Based on safety and pharmacokinetic (PK) results from participants with severe renal impairment (Group 2), Group 3 (Moderate Renal Impairment) and Group 4 (Mild Renal Impairment) will be enrolled if substantial change in the exposure of lasmiditan is observed in participants with severe renal impairment.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3P3P1
- CIUSSS de l'Est-de-l'Ile-de-Montreal - installation Hopital Maisonneuve-Rosemont
-
Mount Royal, Quebec, Canada, H3P3P1
- Algorithme Pharma
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Motivated participant and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
- Male or female participant
- A female participant if of childbearing potential - must be willing to use accepted contraceptive regimens from at least 28 days prior to the drug administration, during the study and for at least 60 days after the dose.
- A male participant with sexual partners who are of child bearing potential must be willing to use accepted contraceptive regimens.
- A male participant agrees to refrain from sperm donation from drug administration until 3 months after the drug administration
- Participant aged of at least 18 years
- Participant with a body mass index (BMI) ≥18.50 kilogram per meter squared (kg/m²) and < 42.00 kg/m²
- Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes or less per day for at least 3 months before Day 1 of this study. An ex smoker is defined as someone who completely stopped smoking for at least 6 months before Day 1 of this study
- Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the participant
Participants with Normal Renal Function:
- Clinical laboratory values within the laboratory's stated normal range; if not within this range, these must be without any clinical significance
- Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, general biochemistry, electrocardiogram [ECG], and urinalysis)
- For each gender, have to match by age (± 10 years) and weight (± 20%) to the pooled mean values of participants with severe renal impairment
- Have an eGFR ≥ 90 mL/min/1.73m² calculated using Modification of Diet in Renal Disease (MDRD) equation at screening
Renal Impaired Participants:
- Considered clinically stable in the opinion of the Investigator
- Presence of mild renal impairment (eGFR 60-89 mL/min/1.73m²), moderate renal impairment (eGFR 30-59 mL/min/1.73m²), or severe renal impairment (eGFR < 30 mL/min/1.73m²) calculated using MDRD equation at screening
Exclusion Criteria:
All Participants:
- Females who are pregnant or are lactating
- History of significant hypersensitivity to lasmiditan or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
- Participant is at imminent risk of suicide (positive response to question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]) or had a suicide attempt within 6 months prior to screening
- Presence or history of any disorder (including Parkinson disease) that could interfere with completion of the study based on the opinion of the Principal Investigator
- Any history of tuberculosis and/or prophylaxis for tuberculosis
- Positive results to human immunodeficiency virus antigen/antibody (HIV Ag/Ab) Combo, Hepatitis B surface antigen (HBsAG (B) (hepatitis B) or Hepatitis C Virus (HCV [C]) tests
- Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before Day 1 of this study
- Females who are pregnant according to a positive pregnancy test
- Participants who took lasmiditan in the previous 28 days before Day 1 of this study
- Participants who took an Investigational Product (in another clinical trial) in the previous 28 days before Day 1 of this study
- Participants who have already participated in this clinical study
- Participants who donated 50 mL or more of blood in the previous 28 days before Day 1 of this study
- Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before Day 1 of this study
Participants with Normal Renal Function:
- Seated pulse rate less than or equal 40 Beats per Minute (bpm) or more than - Seated blood pressure below 90/60 millimeters of mercury (mmHg) or higher than 140/90 mmHg at screening
- Presence of significant gastrointestinal, liver, or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects
- History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability, including but not limited to cholecystectomy
- Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- Presence of out-of-range cardiac interval (PR < 110 milliseconds [msec], PR > 220 msec, QRS < 60 msec, QRS >119 msec and correct QT interval (QTc) > 450 msec for males and > 460 msec for females) on the screening ECG or other clinically significant ECG abnormalities
- Positive screening of alcohol and/or drugs of abuse
- Any clinically significant illness in the previous 28 days before Day 1 of this study
Renal Impaired Participants:
- Seated pulse rate less than 50 bpm or more than 110 bpm at screening
- Seated blood pressure below 90/50 mmHg or higher than 180/110 mmHg at screening
- Currently undergoing any method of dialysis
- History of renal transplant
- History or presence, in the opinion of the Investigator, of significant clinically unstable respiratory, cardiovascular, pulmonary, hepatic, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease,
- Have poorly controlled Type 1 or Type 2 diabetes as defined by Hemoglobin A1c >10%
- Require immunosuppressive medications for treatment of immune-mediated renal disease or kidney transplant recipients
- Evidence of renal carcinoma present at the time of screening
- Have relevant clinical laboratory abnormalities, including any elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin at screening. If the investigator concludes that there is no safety risk for participants with isolated laboratory abnormalities (eg, those that do not reflect end-organ dysfunction; for example, elevated bilirubin in Gilbert's participants) to participate in the study, such cases need to be discussed and approved by the sponsor's medical monitor prior to study enrollment
- Presence of clinically significant physical, laboratory, or ECG finding that, in the opinion of the Investigator and/or sponsor, may interfere with any aspect of study conduct or interpretation of results
- Participants with acute, unstable, or untreated significant medical conditions. Participants requiring treatment for renal impairment or other chronic disease (eg, well-controlled diabetes, hypertension) must be on a stable treatment plan (medicines, doses, and regimens) for at least 2 weeks (except insulin) prior to Day 1 and during the entire study. Small adjustments in the dosages of some concomitant medications may be permitted during the study, and will be discussed on a case-by-case basis. In all cases, the participants' treatment history must be reviewed and their enrollment must be agreed to by both the investigator and the sponsor's medical monitor
- Positive screening of alcohol and/or drugs of abuse unless results can be explained by a prescription medication
- Concurrent use of medications known to affect the elimination of serum creatinine (eg, trimethoprim/sulfamethoxazole [Bactrim®] or cimetidine [Tagamet®]) and competitors of renal tubular secretion (eg, probenecid) within 30 days prior to the first dose of study drug or anticipated need for these therapies through the last pharmacokinetic (PK) sample
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Renal impaired participants
Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
|
200 mg, single oral tablet
Other Names:
|
EXPERIMENTAL: Healthy participants
Participants received single 200 mg oral tablet of lasmiditan.
|
200 mg, single oral tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Maximum observed plasma concentration of lasmiditan.
|
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax)
Time Frame: Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value
|
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Tlast (AUC[0-tlast])
Time Frame: Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Area Under the Concentration Versus Time Curve (AUC) from time zero to tlast (AUC[0- tlast]) of lasmiditan.
|
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf])
Time Frame: Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Area Under the Concentration Versus Time Curve (AUC) from time zero to infinity (AUC[0-inf]) of lasmiditan.
|
Predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 36 hours, postdose
|
Pharmacokinetics: Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae [0-t])
Time Frame: Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Amount excreted in urine (calculated as total lasmiditan concentration multiplied by volume of urine)
|
Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Pharmacokinetics: Fraction of Dose Excreted in Urine (fe)
Time Frame: Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Fraction of dose excreted in urine (Ae / dose)
|
Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Pharmacokinetics: Renal Clearance (CLr)
Time Frame: Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Renal Clearance is the volume of blood or plasma that is completely cleared of the drug by the kidneys per unit time.
(Ae(0-t)/AUC0-T)
|
Predose and intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 and 24 to 36 hours, postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up To 7 days
|
Safety was assessed from time of consent through end of study (up to 7 days).
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs).
A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
|
Up To 7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16895
- CUD-P4-001 (OTHER: Algorithme Pharma)
- COl MIG-113 (OTHER: CoLucid Pharmaceuticals)
- H8H-CD-LAHN (OTHER: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Lasmiditan
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedMigraine With or Without AuraUnited States
-
IlDong Pharmaceutical Co LtdCompletedAcute MigraineKorea, Republic of
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAcute MigraineUnited States
-
Eli Lilly and CompanyAlgorithme Pharma Inc; CoLucid PharmaceuticalsCompletedMigraineUnited States, Canada
-
Hospital Clínico Universitario de ValladolidRecruitingMigraine | Migraine Disorders | Headache Disorders | Migraine With AuraSpain
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedHealthyUnited States
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAn Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR)Migraine DisordersUnited States, United Kingdom, Germany
-
Eli Lilly and CompanyCoLucid Pharmaceuticals; SNBL Clinical Pharmacology Center, Inc.Completed